Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 58 min ago
Peer-reviewedLicence not statedImmunotherapy

Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma

  • Zhiwei Zheng1
  • Lisheng Huang2
  • Yuling Zhang3
  • Huide Zhu1
  • Ling Fang1
  1. 1Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong Province, China
  2. 2Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong Province, China
  3. 3Pharmacy Department, Shantou University Medical College, Shantou, Guangdong Province, China
Read full textDOICite

Related

  1. Effectiveness of lenvatinib versus sorafenib as first- or second-line therapy in hepatocellular carcinoma: insights from real-life data, systematic review, and meta-analysis
    Rosanna Villani, Elisabetta Cornacchia, Nicolò Maria Sguera +4
    Gastroenterology ReportPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  2. Unveiling Novel Molecular Candidate Targets of Loratadine, Raloxifene, and Sorafenib in Hepatocellular Carcinoma.
    Fernanda Villarruel-Melquiades, Martha Noyola-Díaz, Gelacio Martínez-Gudiño +5
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Preoperative Zinc Deficiency as a Novel Prognostic Predictor for Postoperative Recurrence in Hepatocellular Carcinoma
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  4. Precision surgical oncology for hepatocellular carcinoma
    Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
    Xin Xin, Ruoyu Miao
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zheng2026costeffectiveness,
  title = {{Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma}},
  author = {Zhiwei Zheng and Lisheng Huang and Yuling Zhang and Huide Zhu and Ling Fang},
  journal = {Immunotherapy},
  year = {2026},
  month = oct,
  doi = {10.1080/1750743x.2026.2743426},
  url = {https://doi.org/10.1080/1750743x.2026.2743426},
}
RIS
TY  - JOUR
TI  - Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
AU  - Zhiwei Zheng
AU  - Lisheng Huang
AU  - Yuling Zhang
AU  - Huide Zhu
AU  - Ling Fang
PY  - 2026
DA  - 2026/10/04
JO  - Immunotherapy
DO  - 10.1080/1750743x.2026.2743426
UR  - https://doi.org/10.1080/1750743x.2026.2743426
SN  - 1750-743X
SN  - 1750-7448
ER  -